Drug-induced immune hemolytic anemia from piperacillin-tazobactam

Authors

  • Parintorn Nakdee Department of Transfusion Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Kanyapon Suksard Department of Transfusion Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University https://orcid.org/0009-0008-1564-1130
  • Janejira Kittivorapart Department of Transfusion Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University https://orcid.org/0000-0002-4051-8686

Keywords:

Drug-induced immune hemolytic anemia, Antibiotics , Piperacilin-tazobactam, Drug adverse reactions, ภาวะเม็ดเลือดแดงแตกจากยา, ยาปฏิชีวนะ, พิเพอราซิลลิน-ทาโซแบ็กแทม, ภาวะแทรกซ้อนจากยา

Abstract

Abstract:

Drug-induced immune hemolytic anemia (DIIHA) is an uncommon medical condition occurring in approximately 1 to 4 cases per 1,000,000 individuals. DIIHA can occur through various mechanisms. One of the mechanisms is the antibody production against red blood cells, leading to immune hemolysis. This case report describes a patient who, after receiving piperacillin-tazobactam (Tazocin®), developed clinical anemia and hemolysis. A direct antiglobulin test was positive for IgG, and the elution test was negative to all the panel cells. We then performed the drug-treated and presence of drug test to confirm the DIIHA diagnosis. After discontinuing piperacillin-tazobactam, the patient’s clinical condition was improved.

Downloads

Download data is not yet available.

Author Biographies

Parintorn Nakdee, Department of Transfusion Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University

Department of Transfusion Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University

Kanyapon Suksard, Department of Transfusion Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University

Department of Transfusion Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University

References

Garratty G. Drug-induced immune hemolytic anemia. Hematology Am Soc Hematol Educ Program. 2009:73-9.

Cohn CS, Delaney M, Johnson ST, Katz LM, Joseph SW. Technical manual. 21st ed. Bethesda, Maryland: AABB; 2023. P. 453-68.

Murphy WG, Kelton JG. Methyldopa-induced autoantibodies against red blood cells. Blood Rev.1988;2:36-42.

Wu Y, Wu Y, Guo G, Zeng J, Liu Y, Wu Y. Piperacillin-tazobactam induced immune hemolytic anemia led to increased renal impairment and eventual death from multiple organ failure in a patient with hypertensive nephropathy: case report and literature review. BMC Nephrol. 2023;24:173.

Cohn CS, Delaney M, Johnson ST, Katz LM. Technical Manual, 20th ed. [Internet]. Available from: https://ebooks.aabb.org/pdfreader/technical-manual-20th-edition50155278.

Bandara M, Seder DB, Garratty G, Leger RM, Zuckerman JB. Piperacillin-induced immune hemolytic anemia in an adult with cystic fibrosis. Case Rep Med. 2010;2010:161454. doi: 10.1155/2010/161454.

Johnson S, Weitekamp D, Sauer D, Fueger J, Aster R. Piperacillin-dependent antibody with relative especificity reacting with drug-treated red cells and untreated red cells in the presence of drug. Poster session presented at American Association of Blood Banks 47th Annual Meeting; 1994 Nov 12-17; San Diego, CA, USA.

Zanetti RC, Biswas AK. Hemolytic anemia as a result of piperacillin/tazobactam administration: a case report and discussion of pathophysiology. Mil Med. 2013;178(9):e1045-7. doi: 10.7205/MILMED-D-12-00512.

Downloads

Published

2024-11-28

Issue

Vol. 34 No. 4: October-December 2024

Section

รายงานผู้ป่วย (Case report)

License

Copyright (c) 2024 Journal of Hematology and Transfusion Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.